Research finds drug prices increased without adding new clinical benefits
The net prices of five drugs included in a new study from the Institute for Clinical and Economic Review increased without clinical justification in 2023. These increases led to $815 million incremental added costs for U.S. payers.
Related News Articles
Headline
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 editorial criticizing the 340B Drug…
Headline
The White House May 18 announced an expansion of TrumpRx.gov, which now features more than 600 generic drugs. The direct-to-consumer platform serves as a hub…
Headline
The New York Times published a letter to the editor May 16 by AHA President and CEO Rick Pollack that responds to a May 4 op-ed that claimed hospitals are…
Headline
The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party…
Headline
An AHA blog says an essay published in The New York Times wrongly frames hospitals as the leading “culprit” behind rising health care costs. “It…
Blog
A May 4 guest essay published in The New York Times frames hospitals as the leading “culprit” behind rising health care costs. It reduces a complex health…